Subsequently, Pim1 increased the RTK protein expression, including EGFR, HER2, and HER3 through Cap-independent translation, resulting in the resistance of prostate cancer cells to AKT inhibition (Cen et al., 2013). This evidence concerns the gene ERBB2 and prostate carcinoma.